Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apteryx: QLS-111 with Latanoprost in Glaucoma/OHT
NCT06249152Phase 2Completed
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-111 in open-angle glaucoma (OAG), ocular hypertension. Started Apr 2024; status: completed.
02
Drugs
QLS-111
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06249152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249152.